» Articles » PMID: 36148238

The Role of Virus Infections in Sjögren's Syndrome

Overview
Journal Front Immunol
Date 2022 Sep 23
PMID 36148238
Authors
Affiliations
Soon will be listed here.
Abstract

Primary Sjögren's syndrome (pSS) is an autoimmune disease with a clinical picture of not only mainly exocrine gland involvement, with dryness symptoms, but also internal organ and systems involvement. The epithelial damage and releasing of antigens, which, in some circumstances, become autoantigens, underlay the pathogenesis of pSS. The activation of autoimmune processes in pSS leads to the hyperactivation of B cells with autoantibody production and other immunological phenomena such as hypergammaglobulinemia, production of cryoglobulins, or formation of extra-nodal lymphoid tissue. Among the risk factors for the development of this disease are viral infections, which themselves can activate autoimmune reactions and influence the host's immune response. It is known that viruses, through various mechanisms, can influence the immune system and initiate autoimmune reactions. These mechanisms include molecular mimicry, bystander activation, production of superantigens-proteins encoded by viruses-or a programming to produce viral cytokines similar to host cytokines such as, e.g., interleukin-10. Of particular importance for pSS are viruses which not only, as expected, activate the interferon pathway but also play a particular role, directly or indirectly, in B cell activation or present tropism to organs also targeted in the course of pSS. This article is an attempt to present the current knowledge of the influence specific viruses have on the development and course of pSS.

Citing Articles

Possible involvement of Toll-like receptor 8-positive monocytes/macrophages in the pathogenesis of Sjögren's disease.

Yan L, Miyahara Y, Sakamoto M, Kaneko N, Chen H, Sameshima J Front Immunol. 2024; 15:1480675.

PMID: 39544932 PMC: 11560440. DOI: 10.3389/fimmu.2024.1480675.


Immune and non-immune mediators in the fibrosis pathogenesis of salivary gland in Sjögren's syndrome.

Ma D, Feng Y, Lin X Front Immunol. 2024; 15:1421436.

PMID: 39469708 PMC: 11513355. DOI: 10.3389/fimmu.2024.1421436.


Cell therapy in Sjögren's syndrome: opportunities and challenges.

Lu Y, Shi R, He W, An Q, Zhao J, Gao X Expert Rev Mol Med. 2024; 26:e28.

PMID: 39438246 PMC: 11505611. DOI: 10.1017/erm.2024.21.


Vitamin D in Primary Sjogren's Syndrome (pSS) and the Identification of Novel Single-Nucleotide Polymorphisms Involved in the Development of pSS-Associated Diseases.

Dabravolski S, Churov A, Starodubtseva I, Beloyartsev D, Kovyanova T, Sukhorukov V Diagnostics (Basel). 2024; 14(18).

PMID: 39335717 PMC: 11431467. DOI: 10.3390/diagnostics14182035.


Evidence for Molecular Mimicry between SARS-CoV-2 and Human Antigens: Implications for Autoimmunity in COVID-19.

Arevalo-Cortes A, Rodriguez-Pinto D, Aguilar-Ayala L Autoimmune Dis. 2024; 2024:8359683.

PMID: 39247752 PMC: 11380714. DOI: 10.1155/2024/8359683.


References
1.
Ghrenassia E, Martis N, Boyer J, Burel-Vandenbos F, Mekinian A, Coppo P . The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun. 2015; 59:19-25. DOI: 10.1016/j.jaut.2015.01.010. View

2.
Parisis D, Chivasso C, Perret J, Soyfoo M, Delporte C . Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy. J Clin Med. 2020; 9(7). PMC: 7408693. DOI: 10.3390/jcm9072299. View

3.
Schulte-Pelkum J, Fritzler M, Mahler M . Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev. 2009; 8(7):632-7. DOI: 10.1016/j.autrev.2009.02.010. View

4.
Lee S, Lee J, Shin M, Tanaka Y, Park D, Kim T . Detection of HTLV-1 in the labial salivary glands of patients with Sjögren’s syndrome: a distinct clinical subgroup?. J Rheumatol. 2012; 39(4):809-15. DOI: 10.3899/jrheum.111075. View

5.
Roff S, Noon-Song E, Yamamoto J . The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol. 2014; 4:498. PMC: 3888948. DOI: 10.3389/fimmu.2013.00498. View